EmStop Embolic Protection System for TAVR in Aortic Valve Stenosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, multi-center, single-blind randomized trial in up to 25 U.S. sites. Adults with severe aortic valve stenosis are randomized 2:1 to EmStop versus the Sentinel protection device during self-expanding TAVR procedures, with follow-up through 30 days after the procedure. Enrolled participants must meet specific heart function and imaging criteria and procedures are scheduled Monday–Thursday to support neurological assessments. The trial assesses safety and efficacy of EmStop for capturing embolic material during TAVR. Primary comparisons focus on cerebrovascular safety and procedural outcomes related to embolic debris protection.

Why it matters

Who can join: the full rules

Clinical Inclusion Criteria

1. Age ≥ 22 years at the time of consent
2. Meets FDA-approved indications for elective transfemoral self-expanding transcatheter aortic valve replacement (TAVR) procedure on a native or non-native (valve-in-valve) aortic valve. Note: Due to Neurologist availability and importance of capturing the neurological assessments, procedures must be performed Monday-Thursday.
3. Left ventricular ejection fraction ≥ 30% as confirmed by echocardiogram
4. Willing and able to provide written informed consent and written HIPAA authorization prior to initiation of study procedures
5. Willing and able to comply with the protocol-specified procedures and assessments

Imaging Inclusion Criteria

1. Echocardiogram including left ventricular ejection fraction ≥ 30% within 6 months (180 days) prior to the index procedure and prior to randomization to confirm adequate cardiac function.
2. Subjects must undergo a computed tomography angiography (CTA) scan within 6 months (180 days) prior to the index procedure and prior to randomization to confirm anatomic compatibility with the study device and the control device. Subjects must meet the following anatomical inclusion criteria:

EmStop Angiographic (CTA) Inclusion Criteria 1. Subject anatomy is compatible with correct device positioning with:

* Ascending aorta length ≥8 cm
* Femoral and iliac artery minimal lumen diameter of ≥ 8.0 mm
* Ascending aorta/aortic arch diameter is ≥25 or ≤40 mm.
* Ascending aorta or aortic arch exhibits ≤ Grade 1 atheromatous disease and limited wall calcification

Sentinel Angiographic (CTA) Inclusion Criteria

1\. Subject anatomy, excluding bovine arch anatomy, is compatible with correct device positioning with:

* Artery diameter is 9-15 mm for the brachiocephalic artery and 6.5-10 mm in the left common carotid artery
* Arterial stenosis \<70% in either the left common carotid artery or the brachiocephalic artery
* Brachiocephalic or left carotid artery without significant stenosis, ectasia, dissection, or aneurysm at the aortic ostium or within 3 cm of the aortic ostium
* Adequate blood flow to the right upper extremity
* Access vessels without excessive tortuosity

Exclusion Criteria:

1. Requires use of a balloon-expandable transcatheter aortic valve for the index procedure
2. Documented history of stroke or transient ischemic attack (TIA) within the prior 6 months, or any prior stroke with a permanent major disability or deficit (National Institute of Health Stroke Scale \[NIHSS\] \>1 at baseline)
3. Left ventricular ejection fraction \<30%, cardiogenic shock, or hypotension requiring inotropes or mechanical circulatory support, within 3 months prior to index procedure
4. Acute myocardial infarction (MI) within 30 days of the planned index procedure
5. Planned to undergo any other open cardiac surgical or left heart interventional procedure (e.g., concurrent coronary revascularization) during the TAVR procedure or within 30 days prior to the TAVR procedure. The need for a postoperative pacemaker implant after TAVR is not exclusionary.
6. Renal failure, defined as estimated glomerular filtration rate (eGFR) \<30 mL/min
7. Hypercoagulable state that cannot be corrected by additional periprocedural heparin
8. History of intolerance, allergic reaction, or contraindication to any of the study medications, including heparin, aspirin, clopidogrel, or a sensitivity to contrast media or anesthesia that cannot be adequately pre-treated
9. Undergoing therapeutic thrombolysis
10. History of bleeding diathesis or major coagulopathy
11. Hepatic failure (Child-Pugh class C)
12. Active endocarditis or ongoing systemic infection, defined as fever (\>38°C) and/or WBC \>15,000 IU
13. Known allergy to any materials used in the EmStop system (e.g., nitinol)
14. Currently participating in another drug or device clinical study
15. Known or suspected to be pregnant, or is lactating; women of child bearing age must have a negative serum or urine pregnancy test within 48 hours prior to the index study procedure
16. Vulnerable subject populations (e.g., incarcerated or cognitively challenged adults)
17. Any other clinical reasons deemed by the investigators of the study in which the patient would not be an appropriate candidate for the study

Where it's running

• Los Robles Regional Medical Center
  Thousand Oaks, California, United States Recruiting
• Morton Plant Hospital | BayCare Health
  Clearwater, Florida, United States Recruiting
• Ochsner Medical Center
  New Orleans, Louisiana, United States Recruiting
• University of Michigan Health | Michigan Medicine
  Ann Arbor, Michigan, United States Recruiting
• Mission Health
  Asheville, North Carolina, United States Recruiting
• Monument Health Heart and Vascular Institute
  Rapid City, South Dakota, United States Recruiting

Study contacts

• Principal investigator: Stanley J Chetcuti, MD — University of Michigan Health
• Study coordinator: Katherine Vo
• Email: k.vo@emstopeps.com
• Phone: 763-227-9954

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tracking progression and consequences of heart valve disease

  This project will follow adults with moderate or worse valve disease to see if clinical tests and imaging can predict when their condition will get worse.

  Recruiting at 15 sites Second Affiliated Hospital, Zhejiang University, School of Medicine · Fuzhou, Fujian and 14 other locations · NCT07267117

• CardioHeartConnect: Home Peloton cardiac rehab after TAVR

  This trial tests whether an eight-week home-based Peloton program paired with a smartwatch helps people recovering from TAVR become more active and improve heart-related health compared with educational materials.

  Recruiting University of Colorado, Denver · Aurora, Colorado · NCT07008911

• Investigating multiple and mixed heart valve diseases

  This study looks at how common different types of heart valve diseases are and their features by gathering information from patients around the world who have been diagnosed with these conditions.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris, Île-de-France Region · NCT06235385

• Using angiotensin receptor blockers to treat aortic stenosis

  This study is testing if a common heart medication can help people with mild-to-moderate aortic stenosis by slowing its progression and improving heart function.

  Recruiting at 2 sites Phase 4 Institut universitaire de cardiologie et de pneumologie de Québec, University Laval · Québec, Quebec and 1 other locations · NCT04913870

• Transcatheter Aortic Valve Replacement Registry for Outcomes and Quality Monitoring

  This registry collects information from hospitals about patients undergoing TAVR to see how care and outcomes compare to guidelines and nationwide data.

  Recruiting American College of Cardiology · Washington D.C., District of Columbia · NCT07908355

• Exercise and nutrition support before and after TAVI for older adults with aortic stenosis

  This trial tests whether a personalized exercise program plus protein and iron supplements before and after a transcatheter valve replacement can help older adults with aortic stenosis recover better than standard care.

  Recruiting University Hospital of Ferrara · Ferrara, FE · NCT07895719

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.